 PRINCETON, N.J., April 28, 2021 PRNewswire -- Soligenix, Inc. Nasdaq: SNGX Soligenix or the Company, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Senior Vice President and Chief Scientific Officer, Oreola Donini, PhD, delivered a presentation demonstrating the potency of the CiVaxTM COVID-19 vaccine development program in mice and non-human primates NHPs, at the Annual Conference on Vaccinology Research ACVR on April 26-27, 2021. 